Abbott Laboratories (ABT) Wednesday said it will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic.
The test is designed to detect rearrangements of the anaplastic lymphoma kinase gene in advanced non-small cell lung cancer patients who may be eligible for treatment with Pfizer's Xalkori, an oral first-in-class ALK inhibitor.
The Vysis ALK test kit uses Abbott's proprietary fluorescence in situ hybridization technology and was the only diagnostic test used in multi-center global clinical trials in conjunction with Xalkori.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.